Pilgrim’s Pride Set For Growth As Analyst Projects Rising Demand For Chicken

Pilgrim's Pride benefits from high demand for chicken. Analyst gives Buy rating with $41 price target.

Shares of Pilgrim’s Pride Corp (NASDAQ:PPC) remained highly volatile in early trading on Tuesday.

The company is facing high demand for chicken from both full-service restaurants and fast-food chains due to beef shortages, according to Argus Research.

The Pilgrim’s Pride Analyst: John Staszak initiated coverage of Pilgrim’s Pride with a Buy rating and price target of $41.

The Pilgrim’s Pride Thesis: The company should be able to generate low single-digit supply growth over the next five years, Staszak said in the initiation note.

Check out other analyst stock ratings.

Chicken sales could exceed sales of other proteins, like beef, pork and turkey, in mature markets, such as the U.S. and Europe, due to health-conscious consumers preferring chicken, the analyst stated. In emerging markets, chicken sales could be boosted by income growth, he added.

Following supply-chain headwinds in early 2023, Pilgrim’s Pride is poised for margin expansion, Staszak said. “Pilgrim’s Pride is planning to allocate its strong cash flow to growth initiatives and we expect it to exceed its capital expenditures guidance,” he further wrote.

PPC Price Action: Shares of Pilgrim’s Pride had risen by 1.6% to $35.30 at the time of publication on Tuesday.

Photo: Unsplash

Total
0
Shares
Related Posts
Read More

Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck’s Pneumococcal Shots – Analyst Says

The global PCV market, valued at ~$8 billion annually, is poised for significant growth, estimated to reach ~$12 billion soon. Market dynamics are shifting towards adults, potentially doubling with the US discussing vaccination age reduction. Prevnar20 dominates with 97% market share in adults, but Vaxcyte's advanced conjugate capabilities present a competitive advantage.

MRK